A phase I trial of an antisense inhibitor of hepatitis C virus (ISIS 14803), administered to chronic hepatitis C patients
- 31 January 2006
- journal article
- research article
- Published by Elsevier in Journal of Hepatology
- Vol. 44 (1) , 88-96
- https://doi.org/10.1016/j.jhep.2005.09.009
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Hepatitis C. Development of new drugs and clinical trials: Promises and pitfalls. Summary of an AASLD hepatitis single topic conference, Chicago, IL, February 27-March 1, 2003Hepatology, 2004
- Structural biology of hepatitis C virusHepatology, 2004
- Approaches for the sequence-specific knockdown of mRNANature Biotechnology, 2003
- CpG Motifs in Bacterial DNA and Their Immune EffectsAnnual Review of Immunology, 2002
- The Prevalence of Hepatitis C Virus Infection in the United States, 1988 through 1994New England Journal of Medicine, 1999
- Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapyHepatology, 1999
- Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: A comparisonHepatology, 1997
- Fluctations in viral load (HCV RNA) are relatively insignificant in untreated patients with chronic HCV infectionJournal of Viral Hepatitis, 1996
- Inhibition of Hepatitis C Virus Replication by Antisense Oligonucleotide in Culture CellsBiochemical and Biophysical Research Communications, 1995
- Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assayJournal of General Virology, 1993